Stocksigma LogoStocksigma Logo

Dr. Reddy’s Reports Q2FY27 Results and Senior Management Appointment

Dr. Reddy’s Laboratories reported consolidated Q2FY27 revenues of ₹86,708 Mn, down 1.5% YoY but up 7.4% QoQ, impacted primarily by lower lenalidomide sales

Dr. Reddy’s Reports Q2FY27 Results and Senior Management Appointment

Dr Reddys Laboratories Ltd · Outcome · 24 Oct 2026, 12:09 am

Dr. Reddy’s Reports Q2FY27 Results and Senior Management Appointment Dr. Reddy’s Laboratories reported consolidated Q2FY27 revenues of ₹86,708 Mn, down 1.5% YoY but up 7.4% QoQ, impacted primarily by lower lenalidomide sales in North America (down 23% YoY). EBITDA stood at ₹17,828 Mn with a 20.6% margin, while PAT attributable to equity holders fell 36% YoY to ₹9,250 Mn. Net cash surplus reached ₹25.0 Bn as of 30th Sep'26. Additionally, the board approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13th Nov'26.

Original exchange filing (PDF)

More announcements from Dr Reddys Laboratories Ltd

All Dr Reddys Laboratories Ltd announcements